When I pointed at Sirtris Pharmaceuticals in February I was considering to invest in that stock but had no money left. Too bad, since exactly happened what I had suggested: a big player is now trying to buy the company. GlaxoSmithKline today announced that it is going to acquire Sirtris (NASDAQ:SIRT) for $720 million through a cash tender offer of $22.50 per share.

More than 81% profit if you bought that stock yesterday.

Another hot stock is Sirtris Pharmaceuticals. The startup’s activity is discovering and developing proprietary, orally available, small molecule drugs with the potential to treat  metabolic diseases such as Type 2 Diabetes and such of aging by modulating sirtuins, a recently discovered class of enzymes. The drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activating an enzyme called SIRT1, a member of a recently discovered class of enzymes called sirtuins.

All in all Sirtris (NASDAQ:SIRT) is a promising investment in two ways: first its activities are in a field that affects everyone of us sooner or later. Secondly it has just a market capitalization of 340 million dollars – but its competitors are Pfizer (market cap: 152b $), Johnson & Johnson (180 b) and Eli Lilly (58 b). You get the point. One buyout offer and the stock shoots into the sky.